Evidence map›Paper›PMID 40342936›Full record

ReviewBioelectricity2025

Lysosomal Ion Channels and Transporters: Recent Findings, Therapeutic Potential, and Technical Approaches.

Artem Kondratskyi, Andre Bazzone, Markus Rapedius, Rocco Zerlotti, Bastien Masson, Nidish Ponath Sadanandan, Joanne L Parker, Alexandre Santinho, Marine Moutia, Abdou Rachid Thiam and 14 more

Abstract readReview
In one paragraph

Review in Bioelectricity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. pH-dependent regulation in SLC38A9.bioRxiv : the preprint server for biology · 2025
    Article
  7. Bioelectricity, Broadly.Bioelectricity · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Artem KondratskyiNanion Technologies GmbH, Munich, Germany.ORCID https://orcid.org/0000-0003-3290-0524
Andre BazzoneNanion Technologies GmbH, Munich, Germany.
Markus RapediusNanion Technologies GmbH, Munich, Germany.
Rocco ZerlottiNanion Technologies GmbH, Munich, Germany.
Bastien MassonOria Bioscience, Paris, France.
Nidish Ponath SadanandanWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.
Joanne L ParkerDepartment of Biochemistry, University of Oxford, Oxford, UK.
Alexandre SantinhoOria Bioscience, Paris, France.
Marine MoutiaOria Bioscience, Paris, France.
Abdou Rachid ThiamLaboratoire de Physique de l'École Normale Supérieure, ENS, Université PSL, CNRS, Sorbonne Université, Université Paris Cité, Paris, France.
Arlene KempSB Drug Discovery a Sygnature Discovery Business, West of Scotland Science Park, Glasgow, UK.
Fitzwilliam SeibertzNanion Technologies GmbH, Munich, Germany.
Nicoletta MurcianoNanion Technologies GmbH, Munich, Germany.
Søren FriisNanion Technologies GmbH, Munich, Germany.
Nadine BeckerNanion Technologies GmbH, Munich, Germany.
Alison ObergrussbergerNanion Technologies GmbH, Munich, Germany.
Maria BarthmesNanion Technologies GmbH, Munich, Germany.
Cecilia GeorgeNanion Technologies GmbH, Munich, Germany.
Michael GeorgeNanion Technologies GmbH, Munich, Germany.
David DalrympleSB Drug Discovery a Sygnature Discovery Business, West of Scotland Science Park, Glasgow, UK.
Bruno GasnierSaints-Pères Paris Institute for the Neurosciences, Université Paris Cité, Centre National de la Recherche Scientifique, Paris, France.
Simon NewsteadDepartment of Biochemistry, University of Oxford, Oxford, UK.
Christian GrimmWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.
Niels FertigNanion Technologies GmbH, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, there has been a growing interest in lysosomal ion channels and transporters due to their critical role in maintaining lysosomal function and their involvement in a variety of diseases, particularly lysosomal storage diseases, cancer, and neurodegenerative disorders. Recent advancements in research techniques, including manual and automated patch clamp (APC) electrophysiology, solid-supported membrane-based electrophysiology (SSME), and fluorescence-based ion imaging, have further enhanced our ability to investigate lysosomal ion channels and transporters in both physiological and pathological conditions, spurring drug discovery efforts. Several pharmaceutical companies are now developing therapies aimed at modulating these channels and transporters to improve lysosomal function in disease. Small molecules targeting channels like transient receptor potential mucolipin (TRPML) 1 and TMEM175, as well as drugs modulating lysosomal pH, are currently in preclinical and clinical development. This review provides an overview of the role of lysosomal ion channels and transporters in health and disease, highlights the cutting-edge techniques used to study them, and discusses the therapeutic potential of targeting these channels and transporters in the treatment of various diseases. Furthermore, in addition to summarizing recent discoveries, we contribute novel functional data on cystinosin, TRPML1, and two-pore channel 2 (TPC2), utilizing both SSME and APC approaches.

Indexed as

APCelectrophysiologyion channelslysosomepatch clamppumpsSSMEtransporters

Identifiers

PMID40342936
PMCPMC12056583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.